CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 129 enrolled
Drug / intervention
doxorubicin hydrochloride +5 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • Newly diagnosed advanced anaplastic large cell lymphoma
  • CD30+ (Cluster of differentiation antigen 30 positive)
  • Murphy stage III or IV
  • Age under 21 years
Key exclusion· 2
  • B-cell large cell lymphoma
  • Disease limited to the skin

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00059839
NCT00059839Phase 3Completed

A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine

Children's Oncology Group·interventional·Posted May 7, 2003·Updated Sep 22, 2014

In Brief

A Phase 3 clinical trial evaluating doxorubicin hydrochloride, mercaptopurine, and 4 other interventions for Lymphoma. Completed, enrolled 129 participants across 159 sites in 5 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known if combination chemotherapy with vinblastine is more effective than combination chemotherapy with vincristine in treating advanced anaplastic large cell lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens with either vinblastine or vincristine in treating patients who have newly diagnosed advanced anaplastic large cell lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesAustralia, Canada, Puerto Rico, Switzerland, United States

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 7, 2003
Enrollment StartNov 1, 2003
Primary CompletionDec 1, 2009
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 23.2 years ago

Interventions

doxorubicin hydrochloridedrug

Given IV

mercaptopurinedrug

Given by mouth

methotrexatedrug

Given IV and intrathecally

prednisonedrug

Given by mouth

vinblastine sulfatedrug

Given IV

vincristine sulfatedrug

Given IV